Raju Prasad
Stock Analyst at William Blair
(n/a)
# 4,376
Out of 4,820 analysts
12
Total ratings
16.67%
Success rate
-47.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Raju Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DTIL Precision BioSciences | Downgrades: Market Perform | n/a | $5.18 | - | 1 | Jun 9, 2022 | |
| NTLA Intellia Therapeutics | Initiates: Outperform | n/a | $8.48 | - | 1 | Feb 18, 2022 | |
| LOGC ContextLogic | Downgrades: Market Perform | n/a | $7.13 | - | 1 | Feb 3, 2022 | |
| ASMB Assembly Biosciences | Downgrades: Market Perform | n/a | $10.82 | - | 1 | Sep 2, 2021 | |
| VERV Verve Therapeutics | Initiates: Outperform | $92 | $5.73 | +1,505.58% | 1 | Jul 12, 2021 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $46 | $1.80 | +2,455.56% | 1 | Feb 24, 2021 | |
| GBIO Generation Bio Co. | Initiates: Outperform | $45 | $0.43 | +10,314.26% | 1 | Feb 24, 2021 | |
| CRSP CRISPR Therapeutics AG | Initiates: Market Perform | n/a | $37.89 | - | 1 | Mar 14, 2019 | |
| BOLD Boundless Bio | Downgrades: Market Perform | n/a | $1.45 | - | 2 | Nov 7, 2018 | |
| PTCT PTC Therapeutics | Upgrades: Outperform | n/a | $49.70 | - | 2 | Jun 18, 2018 |
Precision BioSciences
Jun 9, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $5.18
Upside: -
Intellia Therapeutics
Feb 18, 2022
Initiates: Outperform
Price Target: n/a
Current: $8.48
Upside: -
ContextLogic
Feb 3, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $7.13
Upside: -
Assembly Biosciences
Sep 2, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $10.82
Upside: -
Verve Therapeutics
Jul 12, 2021
Initiates: Outperform
Price Target: $92
Current: $5.73
Upside: +1,505.58%
Taysha Gene Therapies
Feb 24, 2021
Initiates: Outperform
Price Target: $46
Current: $1.80
Upside: +2,455.56%
Generation Bio Co.
Feb 24, 2021
Initiates: Outperform
Price Target: $45
Current: $0.43
Upside: +10,314.26%
CRISPR Therapeutics AG
Mar 14, 2019
Initiates: Market Perform
Price Target: n/a
Current: $37.89
Upside: -
Boundless Bio
Nov 7, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $1.45
Upside: -
PTC Therapeutics
Jun 18, 2018
Upgrades: Outperform
Price Target: n/a
Current: $49.70
Upside: -